Introduction {#sec1-0300060518786904}
============

Ischemia--reperfusion (I/R) is a pathological process that gives rise to severe ischemic damage in the small intestine. Restoration of blood flow to ischemic tissue may prevent tissue necrosis and facilitate restoration of organ function.^[@bibr1-0300060518786904],[@bibr2-0300060518786904]^ Several molecular markers associated with I/R have been identified.^[@bibr3-0300060518786904][@bibr4-0300060518786904]--[@bibr5-0300060518786904]^ Pentoxifylline (PTF), a methylxanthine derivative, has a hemorheological effect that increases the elasticity of red blood cells and reduces blood viscosity. Decreased blood viscosity results in increased blood flow to the microcirculation and increased tissue oxygenation. The increased elasticity of the red corpuscles causes deformities in these structures. PTF has been used to treat intermittent claudication disorders in Europe since 1972.^[@bibr6-0300060518786904]^ PTF has also been shown to induce vasodilatation and inhibit neutrophil adhesion; these effects have stimulated interest in PTF as a potentially useful compound for treating various I/R-related conditions. In 1995, PTF was used for the first time as an anti-ischemic drug in a small bowel ischemia model in rats.^[@bibr7-0300060518786904]^ The discovery that PTF had an anti-tumor necrosis factor α (TNFα) effect resulted in its use in the treatment of organ ischemia.^[@bibr8-0300060518786904]^ PTF primarily inhibits phosphodiesterase enzymes, which increase the amount of cyclic adenosine monophosphate in polymorphonuclear leukocytes while decreasing free oxygen radical production.^[@bibr9-0300060518786904]^ Recent studies have shown that PTF inhibits xanthine oxidase, thus reducing superoxide and hydroxyl radicals and restoring capillary circulation and tissue oxygenation. Because PTF inhibits free oxygen radicals and phospholipase A2, prostacyclin release is increased.^[@bibr10-0300060518786904]^

In this study, we aimed to determine the influence of PTF on tissue healing by examining the molecular responses to and protective effects of PTF in a rat model of severe intestinal I/R. The role of PTF in severe small bowel ischemia was investigated by evaluating the molecular and pathological parameters in this experimental context. The timing and dose of PTF administration were studied to determine the effect of this molecule under different conditions. Our specific hypothesis was that PTF has a protective effect on small intestinal damage after I/R.

Methods {#sec2-0300060518786904}
=======

This study was approved by the Animal Experiments Local Ethics Committee of Istanbul University (process number 2015/80). The experiments were performed in adherence with the international guidelines for the care and use of laboratory animals at the Laboratory of Surgical Physiopathology.

Thirty-six male Wistar rats (250--350 g) were purchased from the Institute of Experimental Medicine at Istanbul University. Male rats were used because the menstrual cycle may affect blood test results. All rats were housed in metal cages and maintained in a 12-hour dark/light cycle at a controlled temperature of 22°C (±1°C). All rats were given food containing 21% protein and allowed free access to fresh tap water. All cages were cleaned daily. Each cage housed four rats, and rats that were in the same experimental group were housed together.

The rats were randomly assigned to one of six study groups. They were fasted during the night before the surgery. On the day of surgery, the rats were anesthetized with ketamine hydrochloride (50 mg/mL) and xylazine hydrochloride (20 mg/mL) administered by intraperitoneal (IP) injection at a dose of 0.1 mL per 100 g. The rats were then placed in the supine position on a regularly disinfected and surgically draped operating table. Anesthesia and skin sterilization were performed under laboratory conditions for all animals. The animals were not mechanically ventilated. Next, a 4-cm median laparotomy was performed. The small intestine was examined, and the superior mesenteric artery (SMA) was identified and dissected. The SMA was then carefully isolated and clamped while keeping the superior mesenteric vein intact. The small intestine was repositioned into the abdominal cavity. The SMA was clamped for 120 minutes, and reperfusion was initiated by removing the clamp at the end of 120 minutes. Reperfusion was performed for 1 hour before collecting blood to measure the following inflammatory markers: lactic acid dehydrogenase (LDH), which is an indicator of small intestinal damage; tissue malondialdehyde (MDA), which is an indicator of lipid peroxidation and, later, of ischemic damage (it is also indicative of oxidative stress, which can lead to cellular damage after a shift to the pro-oxidant side of the pro-oxidant--anti-oxidant balance); and myeloperoxidase (MPO), which is a quantitative indicator of the presence of neutrophils in the small intestine (it is found in the granules of mammalian neutrophils and plays an important role in the killing abilities of phagocytes). Small bowel specimens were also obtained during blood collection for histological studies.

The rats were divided into the following six groups:

C~1~ control group (n = 6): 0.4 mL of normal saline (NS) was administered by IP injection 60 minutes before intestinal ischemia.

C~2~ control group (n = 6): 0.4 mL of NS was administered by IP injection during reperfusion onset.

P~1~ treatment group (n = 6): 0.4 mL of NS and 1 mg/kg of PTF were administered by IP injection 60 minutes before intestinal ischemia.

P~2~ treatment group (n = 6): 0.4 mL of NS and 1 mg/kg of PTF were administered by IP injection during reperfusion onset.

P~3~ treatment group (n = 6): 0.4 mL of NS and 10 mg/kg of PTF were administered by IP injection 60 minutes before intestinal ischemia.

P~4~ treatment group (n = 6): 0.4 mL of NS and 10 mg/kg of PTF were administered by IP injection during reperfusion onset.

Next, 6 mL of blood from each rat's heart cavity was collected to quantify the levels of serum LDH, MDA, MPO, TNFα, interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). The inflammatory cytokines TNFα, IL-1β, and IL-6 are indicative of an acute inflammatory response to bacteria and other infectious agents. Small intestine specimens were obtained for histological studies and to determine the concentrations of TNFα, IL-1β, IL-6, MDA, and MPO in wet tissue. Blood and tissue samples were taken at the end of reperfusion in all groups. The rats were killed immediately after collection of the blood and tissue samples. Tissue samples were fixed in 10% neutral formaldehyde.

All tissues were washed in phosphate-buffered saline (PBS) at 4°C, placed in a cryogenic tube, and stored at −80°C until analysis. Blood samples were taken from the heart apex while the heart was beating. Samples were then centrifuged at 3,000 to 35,000 rpm for 15 minutes. All serum samples obtained from each animal were placed into three separate Eppendorf tubes and stored at −80°C until analysis.

Preparation of tissue homogenates {#sec3-0300060518786904}
---------------------------------

Tissue samples were homogenized in PBS and formed a 10% (w/v) homogenate. Homogenization was performed with a tissue grinder fitted with a Teflon pestle at a speed of 1000 rpm for 10 minutes.

Serum and intestinal tissue tests {#sec4-0300060518786904}
---------------------------------

The serum LDH level was determined using a cobas 8000 e602 modular automatic analyzer (Roche Diagnostics, Mannheim, Germany). Serum and intestinal tissue levels of TNFα were measured using enzyme-linked immunosorbent assay (ELISA) kits (bms622, bms622TWO, and bms622TEN; Affymetrix eBioscience, San Diego, CA, USA). Serum and tissue levels of IL-6 were determined using ELISA kits (bms625, bms625TWO, and bms625TEN; Affymetrix eBioscience). Serum and tissue levels of IL-1β were determined using ELISA kits (bms630 and bms630TEN; Affymetrix eBioscience). Serum and tissue levels of MPO were determined using ELISA kits (201-11-0575; Shanghai Sunred Biological Technology Co., Ltd., Shanghai, China). Serum and tissue levels of MDA were determined using ELISA kits (201-11-0157; Shanghai Sunred Biological Technology Co., Ltd.).

Histopathological analyses {#sec5-0300060518786904}
--------------------------

Cross-sections (4-µm-thick) of small bowel tissue were stained with hematoxylin and eosin after paraffin embedding. The samples were examined and photographed under a light microscope. Histopathological changes were evaluated in a double-blind manner (blinded assessment of outcomes by two independent assessors). Each section of ischemic intestinal tissue was scored on a 6-point scale as described by Chiu et al.^[@bibr11-0300060518786904]^

Immunohistochemical studies {#sec6-0300060518786904}
---------------------------

Intestinal tissues were dissected, fixed in 10% neutral buffered formalin, embedded in paraffin wax, and then cut into 4-µm-thick sections. The sections were placed onto adhesive slides, deparaffinized in xylene, and rehydrated in a graded alcohol series. Immunoperoxidase staining was performed with an UltraVision Large Volume Detection System: Anti-Polyvalent, HRP (Cat. No. TP-125-HL; Thermo Fisher Scientific, Waltham, MA, USA). Endogenous peroxidase activity was inactivated by incubation in 3% hydrogen peroxide for 10 minutes. The sections were incubated with blocking solution for 5 minutes at room temperature. Next, they were incubated with anti-IL-6 antibody (dilution 1:100; BIOZOL Diagnostica Vertrieb GmbH, Eching, Germany), anti-TNFα antibody (dilution 1:100; BIOZOL), anti-MPO antibody (dilution 1:100; BIOZOL), and anti-IL-1β antibody (dilution 1:100; BIOZOL) overnight at 4°C and washed with PBS the next day. Antibody detection was performed using a biotinylated universal secondary antibody, horseradish peroxidase streptavidin-complex, and amino-ethyl-carbazole as the chromogen. The sections were then counterstained with Mayer's hematoxylin. Normal rabbit IgG (Cat. No. sc-2027; Santa Cruz Biotechnology, Dallas, TX, USA) was used for the negative control.

Histological score analysis {#sec7-0300060518786904}
---------------------------

A Leica DM2500 light microscope was used for histological score analysis, and the samples were photographed with a Leica DFC280 digital camera system (Leica Microsystems, Wetzlar, Germany). The total tissue area of each slide was examined under 400× magnification by two researchers in a blinded manner. The intensity of immunostaining was semiquantitatively evaluated using the following scores: 0 (no staining), 1+ (weak but detectable staining), 2+ (moderate staining), 3+ (distinct staining), and 4+ (intense staining).

Statistical analyses {#sec8-0300060518786904}
--------------------

The Kolmogorov--Smirnov test was used for normally distributed data. The K-sample Kruskal--Wallis test, chi-square test, and analysis of variance were performed to compare the results. Differences were considered statistically significant at a *P* value of \< 0.05. Statistical analyses were performed using SPSS software, version 23.0.1 (IBM Corp., Armonk, NY, USA).

Results {#sec9-0300060518786904}
=======

Biochemical results of blood and small bowel tissue analysis {#sec10-0300060518786904}
------------------------------------------------------------

The TNFα, IL-6, IL-1β, MPO, MDA, and LDH levels measured in blood are shown in [Table 1](#table1-0300060518786904){ref-type="table"}. The TNFα, IL-6, IL-1β, MPO, and MDA levels measured in small bowel tissue are shown in [Table 2](#table2-0300060518786904){ref-type="table"}. Significant differences in serum and tissue molecular responses were found between the P~1~ and C~1~ groups and between the P~3~ and C~1~ groups (both the P~1~ and P~3~ groups were treated with PTF 1 hour prior to ischemia) (*P* \< 0.05 for all) ([Table 3](#table3-0300060518786904){ref-type="table"}). Similarly, significant differences in serum and tissue molecular responses were observed between the P~2~ and C~2~ groups and between the P~4~ and C~2~ groups (both the P~2~ and P~4~ groups were treated with PTF at the beginning of reperfusion) (*P* \< 0.05 for all) ([Table 3](#table3-0300060518786904){ref-type="table"}). These significant differences were the result of elevated molecular responses in the control groups. However, some significant differences were also found between the groups treated with PTF. The blood IL-6 levels were significantly different between the P~1~ and P~3~ groups (*P* = 0.002) and between the P~2~ and P~4~ groups (*P* = 0.009) ([Figure 1](#fig1-0300060518786904){ref-type="fig"}). Furthermore, the blood IL-1β levels were significantly different between the P~1~ and P~3~ groups (*P* = 0.002) and between the P~2~ and P~4~ groups (*P* = 0.002) ([Figure 2](#fig2-0300060518786904){ref-type="fig"}). The blood MDA and LDH levels were significantly different between the P~1~ and P~3~ groups (*P* = 0.002 for both) ([Figures 3](#fig3-0300060518786904){ref-type="fig"} and [4](#fig4-0300060518786904){ref-type="fig"}). The tissue IL-6 and MDA levels were significantly different between the P~2~ and P~4~ groups (*P* = 0.004 and *P* = 0.41, respectively) ([Figures 5](#fig5-0300060518786904){ref-type="fig"} and [6](#fig6-0300060518786904){ref-type="fig"}).

###### 

TNF-α, IL-6, IL-1β, MPO, MDA, and LDH values in blood

![](10.1177_0300060518786904-table1)

  Group     TNF-α (pg/mL) blood   IL-6 (pg/mL) blood   IL-1β (pg/mL) blood   MPO (ng/mL) blood   MDA (nmol/mL) blood   LDH (IU/L) blood   
  --------- --------------------- -------------------- --------------------- ------------------- --------------------- ------------------ ---------
  C~1~      Mean                  99.9501              690.8814              109.2458            16.9432               17.0571            3626.67
  Minimum   88.49                 500.58               60.15                 11.69               12.88                 3349               
  Maximum   109.52                886.01               174.66                19.93               19.50                 4111               
  SD        9.4557                171.24906            37.43625              4.04432             3.03633               271.684            
  P~1~      Mean                  29.2631              556.5951              73.4754             10.7911               14.7067            3626.67
  Minimum   23.00                 424.31               54.64                 10.07               13.90                 3349               
  Maximum   33.12                 691.57               105.94                11.29               15.73                 4111               
  SD        4.96537               101.08608            18.27147              0.46663             0.70075               271.684            
  P~3~      Mean                  26.2691              364.2576              39.5744             11.4578               9.9469             2534.17
  Minimum   18.41                 332.51               31.12                 9.18                5.43                  2152               
  Maximum   31.36                 402.44               53.64                 16.16               12.79                 2891               
  SD        4.36399               23.18632             8.22995               2.56333             3.04749               276.102            
  C~2~      Mean                  97.88134             799.3718              111.2711            23.5673               17.7935            3907.50
  Minimum   88.41                 583.61               97.26                 20.50               13.34                 3331               
  Maximum   108.57                981.71               127.79                29.03               19.88                 4590               
  SD        8.44526               142.82602            11.94735              3.50721             2.45320               526.293            
  P~2~      Mean                  33.1058              483.6291              52.3319             10.4436               13.7249            1393.17
  Minimum   22.73                 436.58               39.86                 7.38                10.45                 1068               
  Maximum   41.45                 543.88               58.39                 12.33               17.40                 1893               
  SD        7.32043               44.90886             7.27652               1.78950             3.13287               285.337            
  P~4~      Mean                  29.0237              397.7390              26.3123             10.6765               13.3382            1466.83
  Minimum   18.41                 364.07               19.08                 7.06                9.59                  1060               
  Maximum   38.57                 451.18               36.16                 13.30               15.69                 1735               
  SD        7.72548               34.05056             6.68781               2.13700             2.10447               269.027            

TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MPO, myeloperoxidase; MDA, malondialdehyde; LDH, lactic acid dehydrogenase; SD, standard deviation.

###### 

TNF-α, IL-6, IL-1β, MPO, and MDA values in small bowel tissue

![](10.1177_0300060518786904-table2)

  Group     TNF-α (pg/g wet tissue)   IL-6 (pg/g wet tissue)   IL-1β (pg/g wet tissue)   MPO (ng/g wet tissue)   MDA (nmol/g wet tissue)   
  --------- ------------------------- ------------------------ ------------------------- ----------------------- ------------------------- ---------
  C~1~      Mean                      258.4168                 2157.2629                 1706.0784               43.6394                   40.8602
  Minimum   220.04                    1723.86                  1546.94                   40.53                   30.00                     
  Maximum   306.75                    2515.67                  1933.20                   49.96                   62.89                     
  SD        39.05984                  364.86257                164.48855                 2.72847                 11.91143                  
  P~1~      Mean                      164.2916                 1506.5400                 1125.5215               34.2044                   29.1258
  Minimum   102.74                    1199.58                  824.02                    27.96                   22.48                     
  Maximum   232.76                    1722.60                  1551.69                   46.88                   35.25                     
  SD        44.88309                  176.88434                284.99781                 7.3757                  5.46783                   
  P~3~      Mean                      170.8501                 1390.7490                 943.8458                29.3180                   24.1189
  Minimum   103.71                    1206.60                  254.72                    22.46                   21.28                     
  Maximum   206.70                    1619.89                  1427.62                   35.71                   27.39                     
  SD        36.40936                  168.22016                426.84843                 4.68998                 2.47575                   
  C~2~      Mean                      277.1872                 2264.1876                 1670.3207               41.1914                   45.4317
  Minimum   254.50                    1757.95                  1324.02                   38.43                   33.41                     
  Maximum   306.75                    2638.20                  1922.45                   49.35                   61.70                     
  SD        22.35718                  381.66622                214.82360                 4.13752                 11.69174                  
  P~2~      Mean                      122.9695                 1313.5731                 998.0197                27.3962                   27.2323
  Minimum   63.87                     1185.20                  517.50                    17.93                   15.89                     
  Maximum   193.68                    1538.77                  1262.80                   35.28                   31.36                     
  SD        52.10958                  158.31216                278.61866                 7.91353                 5.83058                   
  P~4~      Mean                      79.8809                  1145.6868                 818.7325                26.3588                   18.4982
  Minimum   37.99                     1112.16                  348.37                    20.76                   7.69                      
  Maximum   133.02                    1187.17                  1239.58                   32.05                   21.84                     
  SD        40.33132                  24.35077                 391.26796                 4.60748                 5.46513                   

TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MPO, myeloperoxidase; MDA, malondialdehyde; SD, standard deviation.

###### 

Significant improvement in molecular markers between control and pentoxifylline treatment groups

![](10.1177_0300060518786904-table3)

  Groups (*P* values)                                                     TNF-α(pg/mL)   IL-6(pg/mL)   IL-1β(pg/mL)   MPO(ng/mL)   MDA(nmol/mL)   LDH(IU/L)                                   
  ----------------------------------------------------------------------- -------------- ------------- -------------- ------------ -------------- ----------- ------- ------- ------- ------- -------
  C~1~-P~1~-P~3~^[a](#table-fn4-0300060518786904){ref-type="table-fn"}^   0.003          0.006         0.002          0.003        0.011          0.004       0.011   0.010   0.003   0.006   0.003
  C~1~-P~1~^b^                                                            0.004          0.009         0.200          0.002        0.055          0.004       0.004   0.041   0.337   0.041   1.000
  C~1~-P~3~^b^                                                            0.002          0.002         0.002          0.002        0.002          0.002       0.026   0.002   0.002   0.002   0.002
  P~1~-P~3~^b^                                                            0.310          0.699         0.002          0.394        0.002          0.485       0.818   0.394   0.002   0.132   0.002
  C~2~-P~2~-P~4~^[a](#table-fn4-0300060518786904){ref-type="table-fn"}^   0.003          0.002         0.001          0.001        0.001          0.003       0.003   0.003   0.030   0.001   0.003
  C~2~-P~2~^b^                                                            0.002          0.002         0.002          0.002        0.002          0.002       0.041   0.002   0.041   0.002   0.002
  C~2~-P~4~^b^                                                            0.002          0.002         0.002          0.002        0.002          0.002       0.002   0.002   0.015   0.002   0.002
  P~2~-P~4~^b^                                                            0.310          0.180         0.009          0.004        0.002          0.310       0.937   0.589   0.818   0.041   0.699

TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MPO, myeloperoxidase; MDA, malondialdehyde; LDH, lactic acid dehydrogenase.

^a^Kruskal--Wallis test, ^b^Mann--Whitney U test.

![Mean IL-6 (pg/mL) levels in blood (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). IL-6, interleukin-6.](10.1177_0300060518786904-fig1){#fig1-0300060518786904}

![Mean IL-1β (pg/mL) levels in blood (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). IL-1β, interleukin-1 beta.](10.1177_0300060518786904-fig2){#fig2-0300060518786904}

![Mean MDA (nmol/mL) levels in blood (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). MDA, malondialdehyde.](10.1177_0300060518786904-fig3){#fig3-0300060518786904}

![Mean LDH (IU/L) levels in blood (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). LDH, lactic acid dehydrogenase.](10.1177_0300060518786904-fig4){#fig4-0300060518786904}

![Mean IL-6 (pg/g wet tissue) levels in wet tissue (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). IL-6, interleukin-6.](10.1177_0300060518786904-fig5){#fig5-0300060518786904}

![Mean MDA (nmol/g wet tissue) levels in wet tissue (statistically significant differences between the groups are given in [Table 3](#table3-0300060518786904){ref-type="table"}). MDA, malondialdehyde.](10.1177_0300060518786904-fig6){#fig6-0300060518786904}

Histopathological results {#sec11-0300060518786904}
-------------------------

Ischemic damage was significantly reduced in the groups treated with PTF as demonstrated by histological staging. Statistically significant differences were found between the C~1~ group and the P~1~--P~3~ groups as well as between the C~2~ group and the P~2~--P~4~ groups (*P =* 0.004 and *P =* 0.002, respectively). There were significant differences between the P~1~ and C~1~ groups and between the P~3~ and C~1~ groups (*P* = 0.002 and *P* = 0.026, respectively), but not between the P~1~ and P~3~ groups. Similarly, there were statistically significant differences between the P~2~ and C~2~ groups and between the P~4~ and C~2~ groups (*P* = 0.002 for both), but not between the P~2~ and P~4~ groups. The results of the histological staging of I/R injury according to Chiu et al.^[@bibr11-0300060518786904]^ are presented in detail in [Table 6](#table6-0300060518786904){ref-type="table"}.

Immunohistochemistry results {#sec12-0300060518786904}
----------------------------

The immunohistochemical scores of all groups are shown in [Table 4](#table4-0300060518786904){ref-type="table"}. Significant reductions in ischemic damage were observed in the PTF-treated groups as shown by the immunohistochemical scoring (*P* ≤ 0.009 for all) ([Table 5](#table5-0300060518786904){ref-type="table"}). The I/R groups were compared separately. When the IL-1β, IL-6, TNFα, and MPO immunohistochemical scores were evaluated, we also detected significant differences between groups (*P* ≤0.009 for all). Table 4.Immunohistochemical scores in all groupsGroupsImmune score (IL-1β)Immune score (IL-6)Immune score (MPO)Immune score (TNF-α)C~1~Mean3.48003.44003.63003.8340Minimum3.203.203.503.72Maximum3.803.603.804.00SD0.238750.151660.139640.11524P~1~Mean1.08001.95000.94000.7500Minimum0.801.750.700.45Maximum1.402.201.201.00SD0.238750.180280.194940.20000P~3~Mean3.81003.46003.70003.8700Minimum3.603.303.603.75Maximum4.003.603.804.00SD0.151660.114020.093540.12042C~2~Mean3.81003.83003.69003.9600Minimum3.603.703.403.90Maximum4.004.003.904.00SD0.151660.120420.194940.05477P~2~Mean1.24000.89000.52000.1700Minimum1.000.500.400.10Maximum1.801.200.750.25SD0.320940.270190.135090.06708P~4~Mean3.88003.93003.68003.9500Minimum3.703.853.403.85Maximum4.004.003.904.00SD0.130380.067080.219660.07071TotalMean2.88332.97173.04332.7557Minimum0.800.500.400.10Maximum4.004.003.904.00SD1.262411.178231.268911.66371[^1] Table 5.A, B Immunohistochemical score of IL-1β, IL-6, MPO, and TNF-α expression in control and pentoxifylline treatment groupsGroupsImmune score(IL-1β)Immune score(IL-6)Immune score(MPO)Immune score(TNF-α)A C~1~3.48 ± 0.243.44 ± 0.153.63 ± 0.143.83 ± 0.12 P~1~1.08 ± 0.24^a^1.95 ± 0.18^a^0.94 ± 0.19^a^0.75 ± 0.20^a^ P~3~3.81 ± 0.153.46 ± 0.113.70 ± 0.093.87 ± 0.12 *P value0.0040.0080.0070.008*B C~2~3.81 ± 0.153.83 ± 0.123.69 ± 0.193.96 ± 0.05 P~2~1.24 ± 0.32^a^0.89 ± 0.27^a^0.52 ± 0.14^a^0.17 ± 0.07^a^ P~4~3.88 ± 0.133.93 ± 0.073.68 ± 0.223.95 ± 0.07 *P value0.0080.0060.0090.006*[^2] Table 6.Results of histological staging of ischemia--reperfusion injury according to Chiu et al.^[@bibr11-0300060518786904]^Chiu gradeC~1~P~1~P~3~C~2~P~2~P~4~Median514523Minimum414412Maximum545544

A high degree of damage was detected in the immunohistochemical images of samples from the C~1~ group ([Figure 7](#fig7-0300060518786904){ref-type="fig"}). The number of goblet cells and amount of secretion they produced were substantially increased. The morphology of the goblet cells had deteriorated, and the expression of cell type-specific markers was elevated, especially in the lamina propria. Cell damage was more intense in the C~2~ than C~1~ group ([Figure 8](#fig8-0300060518786904){ref-type="fig"}). Severe breakage and deletions were observed in the intestinal villi. Increased IL-1β expression was observed between damaged cells. Abnormal morphology and expression in the lamina propria were also increased. Tissue samples from the P~1~ and P~2~ groups were preserved without deterioration of the tissue integrity and with minimal immunoreactivity ([Figures 7](#fig7-0300060518786904){ref-type="fig"} and [8](#fig8-0300060518786904){ref-type="fig"}). The expression intensity was fairly low. Images showing normal small intestinal morphology were obtained. Although expression of goblet cell markers was somewhat evident in the P~3~ and P~4~ groups, tissue damage was prevented in a similar manner in the P~3~ and P~2~ groups ([Figure 8](#fig8-0300060518786904){ref-type="fig"}). However, partial tissue damage was sustained in the P~4~ group. The morphology of the lamina propria was impaired, and the expression intensity from the lamina propria cells was increased.

![Immunostaining detection images for the C~1~, P~1~, and P~3~ groups. Decreased immunopositivity of IL-1β, IL-6, MPO, and TNF-α expression was observed in both the P~3~ and C~1~ groups but was lower in the P~3~ group. Although the immunopositivity was decreased in the P~3~ group, the damage continued at the tissue level. Streptavidin--biotin peroxidase method. Counterstain: Mayer's hematoxylin. Magnification is ×10 for all photographs. IL-1β, interleukin-1 beta; IL-6, interleukin-6; MPO, myeloperoxidase; TNF-α, tumor necrosis factor alpha.](10.1177_0300060518786904-fig7){#fig7-0300060518786904}

![Immunostaining detection images for the C~2~, P~2~, and P~4~ groups. Decreased immunopositivity of IL-1β, IL-6, MPO, and TNF-α expression was observed in both the P~4~ and C~2~ groups but was lower in the P~4~ group. Although the immunopositivity was decreased in the P~4~ group, the damage continued at the tissue level. Streptavidin--biotin peroxidase method. Counterstain: Mayer's hematoxylin. Magnification is ×10 for all photographs. IL-1β, interleukin-1 beta; IL-6, interleukin-6; MPO, myeloperoxidase; TNF-α, tumor necrosis factor alpha.](10.1177_0300060518786904-fig8){#fig8-0300060518786904}

Discussion {#sec13-0300060518786904}
==========

Recent studies have shown that PTF reduces superoxide and hydroxyl radicals by inhibiting xanthine oxidase in patients in the clinical setting; PTF can result in increased tissue oxygenation and improved capillary filling in cases of strangulation by small bowel closed loop obstruction, ischemic colitis, or intestinal I/R injury.^[@bibr12-0300060518786904][@bibr13-0300060518786904]--[@bibr14-0300060518786904]^ In the present study, our aim was to determine the effects of pentoxifylline on free oxygen radicals and oxidative damage in an I/R model in rats. Our study had three components. First, we collected blood samples to quantify the serum levels of LDH, MDA, MPO, TNFα, IL-1β, and IL-6. We also collected tissue samples from the small bowel to quantify the tissue levels of MDA, MPO, TNFα, IL-1β, and IL-6. Second, we performed histopathological injury scoring for the small bowel. Third, we performed immunohistochemical injury scoring and acquired immunohistochemical images of the small bowel.

A similar experimental study performed by Lloris-Carsí et al.^[@bibr15-0300060518786904]^ in 2013 suggested that PTF protected the small intestine after severe I/R. TNFα, IL-1β, IL-6, MDA, and MPO in both blood and intestinal tissue were investigated in our study, but TNFα, IL-1β, and IL-6 in blood and MDA and MPO in intestinal tissue were investigated in the study by Lloris-Carsí et al.^[@bibr15-0300060518786904]^ Moreover, we added immunohistochemical analyses to the present study to enrich the results of previous studies.

Prior to 2013, the PTF dose range applied in intestinal I/R rat models was approximately 20 to 300 mg/kg body weight. However, in the study performed by Lloris-Carsí et al.,^[@bibr15-0300060518786904]^ PTF doses of 1 and 10 mg/kg were administered. PTF resulted in significant protection against severe ischemic small intestinal damage, even when used during reperfusion onset and at levels not previously reported (10 mg/kg). These effects were evidenced by an improved biochemical and histologic profile. Lower doses of PTF (1 mg/kg) also demonstrated a significant protective effect against inflammation and tissue markers of I/R damage.^[@bibr15-0300060518786904]^ Because PTF doses of 1 and 10 mg/kg had a significant protective effect on severe ischemic small intestinal damage as well as on inflammation and tissue markers of I/R damage, we also used low doses in our study.

Both tissue and blood levels of TNFα, IL-6, and IL-1β (which are indicative of inflammation) improved in all groups treated with PTF before ischemia and at the onset of reperfusion. These results suggest that PTF protects against inflammatory processes in the small bowel. Both tissue and blood levels of MPO, which is a marker of oxidative stress, improved in all groups treated with PTF before ischemia and at the onset of reperfusion. MDA is an indicator of lipid peroxidation levels, and MDA levels are always elevated following tissue damage.^[@bibr16-0300060518786904]^ In an isolated canine gracilis muscle model of I/R, PTF inhibited platelet-activating factor and thus had protective effects.^[@bibr17-0300060518786904]^ In the present study, both the tissue and blood levels of MDA improved in all groups treated with PTF before ischemia and at the onset of reperfusion. The blood levels of LDH, which is indicative of cell damage, improved in all groups treated with PTF before ischemia and at the onset of reperfusion. Cumulatively, these results indicate that PTF protects against cell damage.

The histopathological injury scores for the small bowel in all groups treated with PTF were significantly lower than those in the control group. These results suggest that PTF has a significant role in the prevention of oxidative stress, inflammatory processes, and cell damage in the small bowel.

When we examined the immunohistochemical staining results, we found that tissue integrity with low immunoreactivity was preserved in the P~1~ and P~2~ groups (treated with 1 mg/kg of PTF before ischemia and at the beginning of reperfusion). The immunohistochemical images were similar to the normal small intestinal morphology, indicating that tissue damage was prevented in these groups. We found that tissue damage was partly prevented in the P~3~ group (treated with 10 mg/kg of PTF before ischemia). However, tissue damage was more extensive in the P~4~ group (treated with 10 mg/kg of PTF at the onset of reperfusion), suggesting that a high dose of PTF was not protective against tissue damage. A PTF dose of 10 mg/kg during reperfusion onset produced worse outcomes than a dose of 1 mg/kg. Thus, 10 mg/kg may not provide an adequate blood current or tissue oxygenation in the microcirculation of the small intestine compared with 1 mg/kg. We found that tissue damage was more intense in the C~2~ than C~1~ group, although the same intensity of tissue damage was expected in both control groups. In the C~1~ group, 0.4 mL of NS administered by IP injection 3 hours before the same treatment in the C~2~ group may have induced less tissue damage because of the increased microvascular current in the small intestinal wall. Given our findings of the differences between the P~2~ and P~4~ groups and between the C~1~ and C~2~ groups, we believe that larger sample sizes are necessary to draw a clear conclusion.

This is the first study to use immunohistochemical analyses in a rat model of intestinal I/R for evaluation of the systemic and local expression of inflammatory cytokines and oxidative stress markers of ischemic small bowel injury.^[@bibr7-0300060518786904],[@bibr15-0300060518786904],[@bibr18-0300060518786904][@bibr19-0300060518786904][@bibr20-0300060518786904][@bibr21-0300060518786904]--[@bibr22-0300060518786904]^ Few studies reported in the literature have addressed the role of PTX in small intestinal I/R.^[@bibr7-0300060518786904],[@bibr15-0300060518786904],[@bibr18-0300060518786904][@bibr19-0300060518786904][@bibr20-0300060518786904][@bibr21-0300060518786904][@bibr22-0300060518786904]--[@bibr23-0300060518786904]^ The present study on the mechanisms underlying the protective effect of PTF in small intestinal ischemia specifically suggests that the anti-inflammatory action of PTF is very important. This study indicates that PTX reduces the levels of TNFα, IL-1β, and IL-6 after severe organ ischemia in rats, which may have important implications for ischemia outcomes because these three proinflammatory cytokines are regulators of the inflammatory response in human and animal ischemic cells. Our findings are similar to those of other studies that investigated the effects of PTF on ischemic small bowel injury.^[@bibr7-0300060518786904],[@bibr15-0300060518786904],[@bibr18-0300060518786904][@bibr19-0300060518786904][@bibr20-0300060518786904][@bibr21-0300060518786904]--[@bibr22-0300060518786904]^

The present findings regarding tissue MPO as a marker of neutrophil infiltration and organ responses to PTF are similar to the findings from the previous study performed by Lloris-Carsí et al.^[@bibr15-0300060518786904]^ However, we also examined blood MPO levels and found statistically significant differences. Our findings regarding other markers that were examined to evaluate ischemic damage, such as MDA and LDH, are also similar to the findings from their study.^[@bibr15-0300060518786904]^ Furthermore, we examined MDA in blood and found statistically significant differences.

The main limitation of our research approach was the small number of animals in each group (n = 6), which was suggested by the ethics committee. We believe that as the sample size increases, the statistics will prove to be more significant.

In conclusion, our biochemical, histopathological, and immunohistochemical findings suggest that a low dose of PTF may effectively improve ischemic damage in experimental I/R in rats. We plan to confirm the findings of this study using larger sample sizes in the future.
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[^1]: TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MPO, myeloperoxidase; SD, standard deviation.

[^2]: Values are presented as mean ± standard deviation; All of italic entries emphasize that the value of *P* is statistically significant. ^a^*P* = 0.008 versus C~2~ and P~4~ groups. TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MPO, myeloperoxidase.
